Loading...
StocksRunner logo
 
 
Arcturus Therapeutic
28.77
+7.55%
 
ARCT Arcturus Therapeutics
Last Price
Change
28.77
 
+7.55%
 
 
 

 
Sentiment
 
  Login to display
 
 

25.93

15.88

21.13

16.14

 
 
1m
3m
6m
1y
 

Summary

Arcturus Therapeutics (ARCT) still has no score becuse there is not enough information which allows us to analyze the activity of the stock over a period of time
 

Strengths

Rewards

 Upgraded on attractively valued

 
 

Risk Level

 
StocksRunner
 

Arcturus Therapeutics (ARCT) has High Risk Level

Click here to check what is your level of risk

 

Analysts Opinion

Click on the category for more information
 
 

Earnings

×
 

Earnings

2.00
 
 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

NA
 

StocksRunner

 Has been gaining momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

NA
 
 
 

Analysts Opinion

Analysts opinion is negative but has improved from the past 3 months

 

Street Consensus

Buy
Opinion
Trend
Score
Potential
Score
 
88%
100%
NA
NA
 
On Track
On Track
On Track
 

Street Opinion 

Street view is extremely ish and have negative views on the near-term outlook

 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
Positive vs Negative
 
88%
13%
Positive
Negative
7 out of 8
events present
1 out of 8
events present
 

 
Events Calendar
Click for more information
 
May
S
M
T
W
T
F
S
June
S
M
T
W
T
F
S
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
This Week
26.88
-0.70%
 
Buy Rating
3 Weeks Ago
32.34
+9.96%
 
Weak Earnings
3 Weeks Ago
29.17
+2.28%
 
Top Headlines

hc wainwright & co. reiterates arcturus therapeutics holdings (arct) buy recommendation. fintel reports that on june 1 2023 hc wainwright &. co. reiterated coverage of arcturus therapeutics holdings (nasdaq:arct) with a buy

Fri Jun 2, 2023

Rating

arcturus therapeutics receives fda fast track status for arct-810.

Thu Jun 1, 2023

Activity

analysts vote of confidence: arcturus covid-19 vaccine efforts set to pay off in japan and beyond. ) from neutral to buy with. tuesday the company released its q1 earnings and re

Thu May 11, 2023

Rating

arcturus raised to buy at h.c. wainwright on prospects for covid shot.

Thu May 11, 2023

Rating

hc wainwright & co. upgrades arcturus therapeutics holdings (arct). fintel reports that on may 11 2023 hc wainwright &. co. upgraded their outlook for arcturus therapeutics holdings (nasdaq:arct) from neutral to buy .

Thu May 11, 2023

Rating

arcturus therapeutics (arct) q1 earnings and revenues miss estimates. arcturus therapeutics (arct) came out with quarterly earnings of $0.88 per share missing the zacks consensus estimate of $2.92 per share. this compares to loss of $1

Tue May 9, 2023

Earnings

unlocking arcturus potential and de-risking through partnerships.

Tue Apr 11, 2023

Activity

 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our daily ARCT alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

 
Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

 
Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
About Us

Log In

Sign Up

Contact Us

Terms of use

Privacy Policy

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
StocksRunner

StocksRunner

Get the pulse of the market

 
StocksRunner

ARCT Arcturus Therapeutics

Last Price
28.77
Change
+7.55%
 

Summary

Arcturus Therapeutics (ARCT) still has no score becuse there is not enough information which allows us to analyze the activity of the stock over a period of time

 
 
25.93
15.88
21.13
16.14
 
 
1m
3m
6m
1y
 
Sentiment
 

  Login to display

Strengths

Rewards

 Upgraded on attractively valued

 
 
 
 
Street Consensus
 
Buy
Opinion
Trend
Score
Potential
Score
 
100%
NA
NA
On Track
On Track
On Track
 
88%
13%
Positive
Negative
7 out of 8
events present
1 out of 8
events present
 

Street Opinion

Street view is extremely ish and have negative views on the near-term outlook

 
 
Analysts Opinion
Hover the category for more information
 
 

Earnings

×
 

Earnings

2.00
 
 
 

Rating

×
 

Rating

5.00
 

StocksRunner

 Upgraded on attractively valued

 

Momentum

×
 

Momentum

NA
 

StocksRunner

 Has been gaining momentum

 

Activity

×
 

Activity

4.00
 
 

Future

×
 

Future

NA
 
 
 

Analysts Opinion

Analysts opinion is negative but has improved from the past 3 months

 
 
 
 
 
Events Rating
 
Very Bullish
Bullish
Neutral
Bearish
Very Bearish
 
 
Risk Level
 
StocksRunner
 

Arcturus Therapeutics (ARCT) has High Risk Level.  Click here to check what is your level of risk

 
 
 

Events Calendar

Hover for information

 
May
 
S
M
T
W
T
F
S
 
June
 
S
M
T
W
T
F
S
 
 
 
 
Highlights
Last
Modify
Closing
Price
%
Change

 
Buy Rating
This Week
26.88
-0.70%
 
Buy Rating
3 Weeks Ago
32.34
+9.96%
 
Weak Earnings
3 Weeks Ago
29.17
+2.28%
 
 
 
StocksRunner

Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future

FIND US ON

StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our daily ARCT Alerts

Enter your email to receive daily alerts

 
Home

Leading Gainers

Upgrades

Downgrades

Top Leaders

Categories

Ipo's

Dividend

Option Activity

Insiders Activity

Institutional Holdings

Tags

New Products

FDA Approvals

Agreements

Financial Reports

 
 

Disclaimer: The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
 
 
 

Top Headlines